% | $
Quotes you view appear here for quick access.

Cyclacel Pharmaceuticals, Inc. Message Board

  • redstenox redstenox Dec 3, 2012 11:17 AM Flag

    ►► CYCC (exceptional price target) ◄◄

    CYCC's average Wall Street 12-month SP calculation is $17.50 (nearly a triple on a reverse split adjusted basis), which I believe fair if there is no partner catalyst within the next 12 months. However, if some news enters on the bus-dev front in 2013, a triple could get to $25 pretty quickly.

    The above from today's Seeking Alpha article. Looks like they've done some homework on this one too.

    Nov 1, 2012 recent HOD $7.77 and on Oct 15, 2012 a $7.93 HOD given the corrections on large surges has occurred buying in under $6 is a gift horse. Never look one in the mouth.

    MARKET OUTPERFORM price target $25 inline for the triple sighted above.

    Investors will probably agree with this review using their due diligence/fact checking.


    SortNewest  |  Oldest  |  Most Replied Expand all replies
5.14-0.13(-2.47%)Jun 24 4:00 PMEDT